Arca
Skip to content
Tools
Tools

Ascites

Drug research and approvals for ascites: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 49 studies of ascites are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 0 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 49
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 49 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

2 approved, 4 in phase 3, 7 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Catumaxomab, Spironolactone

Albumin human
Phase 3 Bilirubin sequestering agent
Satavaptan
Phase 3 Vasopressin V2 receptor antagonist
Propranolol
Phase 3 Beta-1 adrenergic receptor antagonist
Midodrine
Phase 3 Adrenergic receptor alpha-1 agonist
Bevacizumab
Phase 2 Vascular endothelial growth factor A inhibitor
Serplulimab
Phase 2 Programmed cell death protein 1 antagonist
Metformin
Phase 2 Mitochondrial complex I (NADH dehydrogenase) inhibitor
Sunitinib
Phase 2 Macrophage colony stimulating factor receptor inhibitor
Empagliflozin
Phase 2 Sodium/glucose cotransporter 2 inhibitor
Rivoceranib
Phase 2 Vascular endothelial growth factor receptor 2 inhibitor
Etilefrine
Phase 2
Tislelizumab
Phase 1 Programmed cell death protein 1 inhibitor

How Its Trials Ended

252 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 69 whose ending is known, 30% met their primary endpoint, 6% missed it and 64% stopped early.

  • Completed, result not reported7329%
  • Status unknown5723%
  • Ongoing5321%
  • Stopped: other or unclear3012%
  • Met its primary endpoint218%
  • Stopped: enrollment or feasibility104%
  • Missed its primary endpoint42%
  • Stopped: lack of efficacy21%
  • Stopped: safety10%
  • Stopped: sponsor or business decision10%

FDA Orphan Designations

Approved first, then open designations, newest first
Dec 14, 2023[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln…Treatment of ascites due to all etiologies except cancerOcelot Bio, Inc.Designated
Apr 14, 2020DocarpamineTreatment of ascites due to all etiologies except cancerMartin Pharmaceuticals, Inc.Designated
Sep 8, 2016TerlipressinTreatment of ascites due to all etiologies except cancerBio Vie Inc.Designated

Medicines Authorised in the EU

Newest first
Feb 10, 2025KorjunyCatumaxomabAtnahs Pharma Netherlands B.V.EMA ↗
May 26, 2023QaialdoSpironolactoneLipomed GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.